OncoMatch/Clinical Trials/NCT06319027
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
Is NCT06319027 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Gadolinium-Chelate for glioblastoma, idh-wildtype.
Treatment: Gadolinium-Chelate — This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors in patients with newly diagnosed glioblastoma. The usual approach for this currently is magnetic resonance imaging (MRI). This study is trying to learn more about the meaning of changes in MRI scans after treatment, as while the appearance of some of these changes may reflect progressing tumor, some may be due the treatment. Dynamic susceptibility contrast (DSC)-MRIs, along with positron emission tomography (PET) and/or magnetic resonance (MR) spectroscopy, may help doctors tell which changes are a reflection of the treatment and which changes may be due to progressing tumor.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Biomarker criteria
Required: IDH1 wild-type
must be IDH wild type
Required: IDH2 wild-type
must be IDH wild type
Required: MGMT methylation status ordered
O6-Methylguanine-DNA Methyltransferase (MGMT) methylation status ordered at time of registration
Prior therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Wisconsin Carbone Cancer Center - University Hospital · Madison, Wisconsin
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify